Sarah R. London and Paulina do Amaral of the national plaintiffs’ law firm Lieff Cabraser Heimann & Bernstein, LLP, announce that Paul Ramirez and Dulce A. Morga, residents of Los Angeles County, California, have filed a personal injury lawsuit against pharmaceutical giant GlaxoSmithKline LLC (“GSK”) for injuries leading to the death of their infant daughter, Baby Sarah Ramirez Morga, allegedly as a result of Ms. Morga being prescribed GSK’s drug ondansetron (brand name Zofran) while pregnant.
Sarah R. London and Paulina do Amaral of the national plaintiffs’ law firm Lieff Cabraser Heimann & Bernstein, LLP, announce that Robin and Stanley Zgurski, residents of Florida, have filed a personal injury lawsuit against pharmaceutical giant GlaxoSmithKline LLC (“GSK”) for the injuries suffered by their son allegedly as a result of Ms. Zgurski being prescribed GSK’s drug ondansetron (brand name Zofran) while pregnant. [Read more…]
As reported by Law360, the US Judicial Panel on Multidistrict Litigation has consolidated in Massachusetts a number of lawsuits alleging that off-label promotion by GlaxoSmithKline of its anti-nausea drug Zofran for morning sickness led to serious birth defects. “The MDL panel found that 12 lawsuits, some of which are proposed class actions, warranted consolidation as they all involved common allegations that GlaxoSmithKline’s Zofran and its generic equivalent, Ondansetron … cause birth birth defects in children when their mothers ingest the drug while pregnant.” [Read more…]
Sarah R. London of the national plaintiffs’ law firm Lieff Cabraser Heimann & Bernstein, LLP, announced that Katherine and Matthew Murray, residents of Alameda County, California, have filed a personal injury lawsuit against pharmaceutical giant GlaxoSmithKline LLC (“GSK”) for the injuries suffered by their daughter allegedly as a result of Ms. Murray being prescribed while pregnant GSK’s drug ondansetron, sold under the brand name Zofran.
The story behind a drug called Risperdal has a long and winding tail. And it is a story that has had devastating results for many American families.
Benicar is a widely prescribed medication for blood pressure and hypertension (chronic high blood pressure). Olmesartan is the active ingredient of Benicar and is also contained in Benicar HCT, Tribenzor, and Azor.
Lieff Cabraser attorney Lexi J. Hazam is speaking at HarrisMartin’s MDL Conference: Zofran, Bard IVC and Zimmer Persona Knee Litigation on July 29, 2015 at Hotel Nikko in San Francisco. Hazam will be featured as a panelist discussing the Benicar (Olmesartan) Litigation. Hazam has been appointed by the court overseeing the nationwide Benicar MDL litigation to the Plaintiffs’ Steering Committee, and serves as Co-Chair of the MDL Plaintiffs’ Science and Experts Committee.
In a significant development in the Actos litigation, the California State Appeals Court for the Second District last week reinstated a cancer patient and spouse’s $6.5 million jury award against the makers of Actos, a diabetes medication. The appellate court’s decision reaffirms the importance and role of the jury in deciding claims.
Lieff Cabraser attorney Lexi J. Hazam was elected Vice Chair of the American Association for Justice’s (AAJ) Section on Toxic, Environmental and Pharmaceutical Torts (STEP). Promoting a fair and effective justice system, AAJ’s mission is to support the representation of those injured by the harmful misconduct and negligence of others. STEP is a section of the association, which focuses on pharmaceutical toxic effects, medical devices, pesticides, consumer products, industrial pollution, and other environmental damages.
Parents charge that Zofran (generic name ondansetron) is a dangerous and defective drug because its use by pregnant women can lead to serious birth defects. Zofran was approved by the FDA in 1991 to treat extreme nausea from chemotherapy and later expanded for use as a treatment for serious surgical nausea. Lawsuits allege that the drug has been marketed off-label by GlaxoSmithKline to obstetricians and gynecologists to prescribe to their pregnant patients to control the pregnancy nausea commonly referred to as “morning sickness.”
Patients charge that Xarelto is a dangerous and defective drug because in certain patients it triggers uncontrolled bleeding and other life-threatening complications. Xarelto was approved in July 2011 to prevent blood clots in patients undergoing knee and hip surgeries, and its use has been expanded, including to patients with irregular heartbeats or facing a strong likelihood of blood clots in the legs or lungs.
Lieff Cabraser attorney Lexi J. Hazam announced that three patients prescribed olmesartan, a widely-prescribed blood pressure medication sold under the brand name Benicar, along with Benicar HT, Tribenzor and Azor, recently filed lawsuits against Japan-based Daiichi Sankyo, Benicar’s manufacturer, and Forest Laboratories, which marketed and distributed Benicar in the United States.
The U.S. Food and Drug Administration has warned that patients with high blood pressure taking Benicar could suffer serious side effects including chronic diarrhea, unusual weight loss, and severe gastrointestinal problems.
The California Supreme Court today resoundingly endorsed consumers’ right to challenge pharmaceutical pay-for-delay settlements under California competition law.
On April 28, 2015, U.S. District Court Judge Rebecca F. Doherty, the judge overseeing the Actos injury cases in federal court nationwide, issued an order recognizing that Takeda, the manufacturer of Actos, has agreed to settle all bladder cancer claims brought against the company by Actos users who satisfy the following three conditions:
Zofran has become a widely popular morning sickness treatment. Physician expectations were that the anti-nausea drug would benefit the patient, but GlaxoSmithKline, the manufacturer of Zofran, allegedly provided little information on the drug’s effect on unborn children. In numerous lawsuits, parents charge that GlaxoSmithKline failed to warn about an association between Zofran and certain very specific birth defects such as cleft palate and heart defects.
Lieff Cabraser attorney Lexi J. Hazam will be discussing the Benicar prescription drug litigation at the 15th Anniversary of the Mass Torts Made Perfect Seminar on April 17, 2015 in Las Vegas, Nevada. Attorneys from across the nation attend the annual conference to learn from leaders of the plaintiffs’ bar of the latest developments in lawsuits involving defective and dangerous prescription drugs, medical devices, and other products that collectively have injured tens of thousands of Americans.
Lieff Cabraser attorney Lexi J. Hazam will be speaking at HarrisMartin’s MDL Conference: Xarelto, Morcellators and Emerging Torts on March 25, 2015 at The Westin San Diego. Hazam will be featured on a panel discussing the prescription drug Benicar. Hazam will also be addressing the science behind the plaintiffs’ claims.
A Philadelphia jury returned a $2.5 million verdict against healthcare giant Johnson & Johnson for a 20-year-old autistic man from Alabama who allegedly developed large breasts as a teenager while prescribed the antipsychotic medication Risperdal. The lawsuit charged that Johnson & Johnson failed to warn consumers of the distressing side effects that Risperdal causes, concealing from officials the dangerous and defective risks involved when taking the prescribed medication.
Attorney Wendy R. Fleishman of the national plaintiffs’ law firm Lieff Cabraser Heimann & Bernstein, LLP, announced that four young men prescribed the antipsychotic medication Risperdal recently filed separate personal injury lawsuits alleging that Risperdal is a defective and dangerous prescription drug. The complaints were brought against Johnson & Johnson and its subsidiary Janssen Pharmaceuticals, the manufacturer of Risperdal, in state court in Pennsylvania, where Janssen Pharmaceuticals is located. [Read more…]